Vivos Therapeutics, Inc. (VVOS) Stock Forecast
VVOS analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.33 / 5 from 3 analysts
- Price target
- $2.12 average of analyst targets
- Upside to target
- +1,515.8% from the latest close
- Next earnings
- November 18, 2026 EPS estimate $-0.28
- 52-week range
- $0.13 – $3.01
VVOS analyst ratings
3 analystsNumber of analysts at each rating.
VVOS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VVOS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.30 | −$0.54 | −$0.12 | −$0.49 | +38.3% | 4 |
| Current fiscal year (2026) | −$1.34 | −$2.14 | −$0.75 | −$2.07 | +35.1% | 4 |
| Next fiscal year (2027) | −$0.82 | −$2.17 | −$0.10 | −$1.34 | +38.7% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VVOS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $5.5M | $5.5M | $5.5M | −19.3% | 1 |
| Current fiscal year (2026) | $21.8M | $21.8M | $21.8M | +24.9% | 1 |
| Next fiscal year (2027) | $34.1M | $24.5M | $45.1M | +56.4% | 3 |
VVOS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VVOS revenue: reported and forecast
VVOS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.25 | −$0.42 | −$0.30 | −$0.30 | −$0.30 | +19.4% | 0 up · 0 down |
| Current fiscal year (2026) | −$1.15 | −$1.82 | −$1.39 | −$1.39 | −$1.34 | +16.4% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.35 | −$0.84 | −$0.79 | −$0.79 | −$0.82 | +135.2% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VVOS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VVOS beat in 5 of 12.
What analysts expect from VVOS
3 analysts cover Vivos Therapeutics; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $2.12, 1,515.8% above the latest close of $0.13. Analysts expect earnings of −$1.34 per share for 2026, +35.1% from a year earlier. For 2027 the average estimate is −$0.82 per share on revenue of $34.1 million. Vivos Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: VVOS income statement, VVOS key metrics, VVOS chart. See the VVOS stock overview for the latest quote and news.
VVOS forecast FAQ
What is Vivos Therapeutics's price target?
The average analyst price target for Vivos Therapeutics is $2.12, 1,515.8% above the latest close of $0.13.
Is Vivos Therapeutics a buy, hold or sell?
Of 3 analysts covering Vivos Therapeutics, 2 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Vivos Therapeutics's EPS forecast?
Analysts forecast −$1.34 per share for 2026 (range −$2.14 to −$0.75); for 2027 the estimate is −$0.82.
What is Vivos Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $21.8 million, growth of 24.9%; for 2027 it is $34.1 million.
When does Vivos Therapeutics report earnings?
Vivos Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 18, 2026; the EPS estimate is $-0.28.
Does Vivos Therapeutics usually beat earnings estimates?
Vivos Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.